Market Spotlight: Hodgkin’s Lymphoma
Market Spotlight: Hodgkin’s Lymphoma
$1,318.00
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, regulatory events, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 82,100 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028.
- In the same year, there were approximately 281,800 five-year prevalent cases of Hodgkin’s lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.
- The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/TNFRSF8, microtubules (tubulin), DNA, the immune system, and programmed death-1 receptor/programmed death ligands (PD-L1 and PD-L2). The majority of the approved drugs are administered via the intravenous route.
- There are only four industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma, with one in Phase I and three in Phase II.
- Therapies in the pipeline for Hodgkin’s lymphoma focus on a variety of targets. These therapies are being tested in intravenous, subcutaneous, and intratumoral formulations.
- The overall likelihood of approval of a Phase I hematologic asset is 7.8%, and the average probability a drug advances from Phase III is 56%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.7 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 52 trials.
- Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin’s lymphoma, followed by Bristol Myers Squibb.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Chemotherapy
10 Radiation therapy
10 Immunotherapy
11 Stem cell transplantation (SCT)
12 EPIDEMIOLOGY
16 MARKETED DRUGS
20 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Ukoniq for Hodgkin’s Lymphoma (April 15, 2022)
24 AFM13 for Hodgkin’s Lymphoma (April 10, 2022)
26 AFM13 for Hodgkin’s Lymphoma (April 9, 2021)
27 Camidanlumab Tesirine for Hodgkin’s Lymphoma (December 6, 2020)
30 KEY REGULATORY EVENTS
30 Scotland’s HTA Body Accepts MSD’s Keytruda For Hodgkin’s Lymphoma
30 Zimberelimab Receives Approval In China For Hodgkin’s Lymphoma
30 China Approves Fifth Domestic PD-1 Drug
31 PROBABILITY OF SUCCESS
32 REVENUE OPPORTUNITY
34 CLINICAL TRIAL LANDSCAPE
35 Sponsors by status
36 Sponsors by phase
37 Recent events
38 BIBLIOGRAPHY
39 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of Hodgkin’s lymphoma, 2019–28
20 Figure 2: Overview of pipeline drugs for Hodgkin’s lymphoma in the US
20 Figure 3: Pipeline drugs for Hodgkin’s lymphoma, by company
21 Figure 4: Pipeline drugs for Hodgkin’s lymphoma, by drug type
21 Figure 5: Pipeline drugs for Hodgkin’s lymphoma, by classification
27 Figure 6: AFM13 for Hodgkin’s Lymphoma (April 9, 2021): Phase I – University of Texas
29 Figure 7: Camidanlumab Tesirine for Hodgkin’s Lymphoma (December 6, 2020): Phase II – R/R HL
31 Figure 8: Probability of success in the hematologic pipeline
34 Figure 9: Clinical trials in Hodgkin’s lymphoma
34 Figure 10: Top 10 drugs for clinical trials in Hodgkin’s lymphoma
35 Figure 11: Top 10 companies for clinical trials in Hodgkin’s lymphoma
35 Figure 12: Trial locations in Hodgkin’s lymphoma
36 Figure 13: Hodgkin’s lymphoma trials status
37 Figure 14: Hodgkin’s lymphoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of Hodgkin’s lymphoma, 2019–28
15 Table 2: Five-year prevalent cases of Hodgkin’s lymphoma, 2019–28
17 Table 3: Marketed drugs for Hodgkin’s lymphoma
22 Table 4: Pipeline drugs for Hodgkin’s lymphoma in the US
24 Table 5: Ukoniq for Hodgkin’s Lymphoma (April 15, 2022)
25 Table 6: AFM13 for Hodgkin’s Lymphoma (April 10, 2022)
26 Table 7: AFM13 for Hodgkin’s Lymphoma (April 9, 2021)
28 Table 8: Camidanlumab Tesirine for Hodgkin’s Lymphoma (December 6, 2020)
32 Table 9: Historical global sales, by drug ($m), 2017–21
33 Table 10: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Systemic Lupus Erythematosus (SLE) 
Sign up to the